Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2021

View Archived Issues

Phase III DARE-19 study of Farxiga in COVID-19 does not meet primary endpoints

Topline data presented from phase II KINETIC study of SAGE-324 in essential tremor

Biosion presents nano-antibodies targeting B-cell maturation antigen

Nanjing Huawe Medicine Technology Development patents IAP inhibitors

Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare present new GTPase KRAS inhibitors

New antibiotic prodrugs synthesized at Brandeis University

New acid ceramidase inhibitors identified by BIAL Biotech, Istituto Italiano di Tecnologia

BAY-2476568, a reversible, potent and selective EGFR inhibitor for lung cancer

Toripalimab approved in China for locally advanced or metastatic urothelial carcinoma

Gut peptide shown to improve metabolic disease in mice

Positive phase II data for mavrilimumab in nonmechanically ventilated severe COVID-19

Turning Point opens phase I/II study of ALK inhibitor TPX-0131

Remdesivir metabolite GS-441524 may be superior for eradicating SARS-CoV-2

Health Canada authorizes initiation of clinical studies of apabetalone for COVID-19

Akston initiates phase I/II trial of COVID-19 vaccine candidate AKS-452

First-in-human data presented for EOS-884448 in immune-resistant advanced cancers

PC-14586 leads to robust tumor regression in NUGC3 xenografts

EpiEndo begins first-in-human trial of EP-395 for chronic airway diseases

AZD-5305 shows excellent efficacy in BRCA-mutant xenografts

Characterization of cryo-EM structures of OX2R bound to peptide and small-molecule agonists

scRNA-seq and gene expression analysis of lung immune cells in a model of RA-associated lung disease

VBI reports phase Ib/IIa data on VBI-2601 in hepatitis B

PRINCIPLE study: inhaled budesonide shortens recovery time in nonhospitalized COVID-19 patients

PYC's PPMO technology delivers high levels of RNA therapeutic to brain in preclinical study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...